COHERUS BIOSCIENCES, INC. (NASDAQ:CHRS) Files An 8-K Results of Operations and Financial Condition

COHERUS BIOSCIENCES, INC. (NASDAQ:CHRS) Files An 8-K Results of Operations and Financial Condition
Item 2.02 Results of Operations and Financial Conditions

Story continues below

On August7, 2017, Coherus BioSciences, Inc. issued a press release regarding its financial results for its second quarter ended June30, 2017. The full text of the press release is furnished as Exhibit 99.1 to this Form 8-K.

This information in this Item 2.02 of this Form 8-K and the Exhibit 99.1 attached hereto shall not be deemed “filed” for purposes of Section18 of the Securities and Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section, or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

Item 2.02 Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No.

Description

99.1 Press release dated August7, 2017.


Coherus BioSciences, Inc. Exhibit
EX-99.1 2 d421981dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 Coherus BioSciences Reports Second Quarter 2017 Corporate Highlights and Financial Results REDWOOD CITY,…
To view the full exhibit click here

About COHERUS BIOSCIENCES, INC. (NASDAQ:CHRS)

Coherus BioSciences, Inc. is a late-stage clinical biologics platform company. The Company is focused on the global biosimilar market. The Company operates through developing and commercializing biosimilar products segment. Its business is organized around therapeutic franchises, including Oncology biosimilar candidates pegfilgrastim (Neulasta), in late clinical-stage, and bevacizumab (Avastin), in preclinical-stage; Immunology (Anti-TNF) biosimilar candidates, etanercept (Enbrel) and adalimumab (Humira), which are both in late clinical-stage; Ophthalmology biosimilar candidate ranibizumab (Lucentis) in preclinical stage, and Multiple sclerosis small molecule therapeutic candidate, CHS-131 (formerly INT-131), in Phase II proof-of-concept trial. Its long-acting granulocyte colony-stimulating factor (G-CSF) product candidate, CHS-1701, is a pegfilgrastim (Neulasta) biosimilar. Its clinical-stage pipeline consists of two anti-Tumor Necrosis Factors (anti-TNFs).

An ad to help with our costs